For instance, the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) and the Canagliflozin Cardiovascular Assessment Study (CANVAS) have shown that sodium-glucose cotransporter-2 (SGLT-2) inhibitors, a class of antidiabetic agents, not only improve glycemic control but also confer cardiovascular benefits, including a reduction in the risk of heart failure and cardiovascular death [7-9]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.